Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Urothelial Cancer × enfortumab vedotin × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Transitional Cell 23 Urinary Bladder Neoplasms 16 Ureteral Neoplasms 7 Urethral Neoplasms 3 Urologic Neoplasms 2 Parkinson Disease 4, Autosomal Dominant Lewy Body 2 Neoplasms 2 Neoplasm Metastasis 2 Muscle Invasive Bladder Urothelial Carcinoma 2 Metastatic Urothelial Cancer 2 Carcinoma, Renal Cell 2 Carcinoma, Non-Small-Cell Lung 2 Breast Neoplasms 2 Advanced Bladder Cancer 2 Urothelial Cancer 1 Urogenital Neoplasms 1 Urachal adenocarcinoma 1 Triple Negative Breast Neoplasms 1 Salivary Gland Neoplasms 1 Renal Pelvis and Ureter Urothelial Carcinoma 1 Peripheral Nervous System Diseases 1 Penile Squamous Cell Carcinoma (PSCC) 1 Penile Neoplasms 1 Pancreatic Neoplasms 1 Non-Muscle Invasive Bladder Neoplasms 1 Muscle-invasive Bladder Cancer 1 Metastatic Urothelial Cancer and Other Malignant Solid Tumors 1 Metastatic Castration-resistant Prostate Cancer 1 Melanoma 1 Head and Neck Neoplasms 1

Interventions

Gemcitabine 4 Cisplatin 4 Carboplatin 3 pembrolizumab 2 erdafitinib 2 durvalumab 2 vinflunine 1 tremelimumab 1 niraparib 1 enfortumab vedotin 1 cabozantinib 1 avelumab 1 atezolizumab 1 Tiragolumab 1 Sunitinib 1 Radiotherapy 1 Paclitaxel 1 Nivolumab 1 Midazolam 1 Metformin 1 Ipilimumab 1 Everolimus 1 Docetaxel 1 4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04223856 2025-06-13

EV-302

Astellas Pharma Inc

Phase 3 Active not recruiting

886 enrolled 12 charts 1 FDA

Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡